Ironwood Pharmaceuticals Inc
IRWD
ISIN null / Valor 10773079
Ironwood Pharmaceuticals Inc
UMushroom community rating:
About company
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal disorders. The company is best known for discovering and developing linaclotide, marketed as Linzess for the treatment of irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC), which serves as a principal source of revenue through product sales, royalties and collaboration agreements. Ironwood maintains a research and development pipeline of earlier‑stage candidates aimed at GI motility and related pain mechanisms, funds its operations through a combination of product-derived revenues and strategic partnerships/license arrangements, and is headquartered in the Boston area.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
724 M
Market cap (USD)
1,738,092
Daily traded volume (Shares)
4.495 / 4.34
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Kian Mazloum
David Cann
EQUITIES OF THE SAME SECTOR
